Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Candesartan cilexetil & hydrochlorothiazide
All strengths: General benefit; same patient cost rules
Shared coverage and patient cost rules
StatusGeneral benefit
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Atacand Plus · DIN 02244021 · 16 mg & 12.5 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
1 brand, same coverage
Atacand Plus · DIN 02244021
Manufacturer: Cheplapharm Arzneimittel GmbH; listing date 2002-07-29
Health Canada: Marketed since 2025-06-10 · brand ATACAND PLUS · ATC C09DA06 CANDERSARTAN AND DIURETICS, C09DA06 CANDERSARTAN AND DIURETICS · form Tablet · route Oral · ingredients HYDROCHLOROTHIAZIDE 12.5 MG, CANDESARTAN CILEXETIL 16 MG · company Cheplapharm arzneimittel gmbh · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordMinistry pays: $0.2156 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02244021)
Source record
DIN 02244021: Atacand Plus
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800248; group id 315; item number 0696; lccId None; manufacturer id CHE
Source form: Tab; strength: 16mg & 12.5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $1.6162; ministry $0.2156
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02244021
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=67964
Interchangeable products
Auro-Candesartan HCT · DIN 02421038 · $0.2156
Candesartan HCT · DIN 02394812 · $0.2156
Candesartan/HCTZ · DIN 02394804 · $0.2156
Jamp Candesartan-HCT · DIN 02473240 · $0.2156
NRA-Candesartan HCTZ · DIN 02531240 · $0.2156
PMS-Candesartan-HCTZ · DIN 02391295 · $0.2156
Sandoz Candesartan Plus · DIN 02327902 · $0.2156
Teva-Candesartan/HCTZ · DIN 02395541 · $0.2156
Shortage status: resolved shortage (ended March 13, 2019); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02244021
Shortage record checked October 6, 2026
Auro-Candesartan HCT · DIN 02421038 · 16 mg & 12.5 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Auro-Candesartan HCT · DIN 02421038
Manufacturer: Auro Pharma Inc.; listing date 2015-05-28
Health Canada: Marketed since 2015-03-17 · brand AURO-CANDESARTAN HCT · ATC C09DA06 CANDERSARTAN AND DIURETICS, C09DA06 CANDERSARTAN AND DIURETICS · form Tablet · route Oral · ingredients HYDROCHLOROTHIAZIDE 12.5 MG, CANDESARTAN CILEXETIL 16 MG · company Auro pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordAuro-Candesartan HCT: Formulary list price $0.22 per unit (the source does not state the unit; exact figure $0.2156). What the ministry pays, not the patient.
Ministry pays: $0.2156 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02421038)
Source record
DIN 02421038: Auro-Candesartan HCT
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800248; group id 315; item number 0696; lccId None; manufacturer id AUR
Source form: Tab; strength: 16mg & 12.5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2156; ministry $0.2156
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02421038
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90562
Interchangeable products
Atacand Plus · DIN 02244021 · $0.2156
Candesartan HCT · DIN 02394812 · $0.2156
Candesartan/HCTZ · DIN 02394804 · $0.2156
Jamp Candesartan-HCT · DIN 02473240 · $0.2156
NRA-Candesartan HCTZ · DIN 02531240 · $0.2156
PMS-Candesartan-HCTZ · DIN 02391295 · $0.2156
Sandoz Candesartan Plus · DIN 02327902 · $0.2156
Teva-Candesartan/HCTZ · DIN 02395541 · $0.2156
Shortage status: resolved shortage (ended February 18, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02421038
Shortage record checked October 6, 2026
Candesartan HCT · DIN 02394812 · 16 mg & 12.5 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Candesartan HCT · DIN 02394812
Manufacturer: Sivem Pharmaceuticals ULC; listing date 2020-06-30
Health Canada: Marketed since 2012-10-18 · brand CANDESARTAN HCT · ATC C09DA06 CANDERSARTAN AND DIURETICS, C09DA06 CANDERSARTAN AND DIURETICS · form Tablet · route Oral · ingredients HYDROCHLOROTHIAZIDE 12.5 MG, CANDESARTAN CILEXETIL 16 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordCandesartan HCT: Formulary list price $0.22 per unit (the source does not state the unit; exact figure $0.2156). What the ministry pays, not the patient.
Ministry pays: $0.2156 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02394812)
Source record
DIN 02394812: Candesartan HCT
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800248; group id 315; item number 0696; lccId None; manufacturer id SIV
Source form: Tab; strength: 16mg & 12.5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2156; ministry $0.2156
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02394812
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87997
Interchangeable products
Atacand Plus · DIN 02244021 · $0.2156
Auro-Candesartan HCT · DIN 02421038 · $0.2156
Candesartan/HCTZ · DIN 02394804 · $0.2156
Jamp Candesartan-HCT · DIN 02473240 · $0.2156
NRA-Candesartan HCTZ · DIN 02531240 · $0.2156
PMS-Candesartan-HCTZ · DIN 02391295 · $0.2156
Sandoz Candesartan Plus · DIN 02327902 · $0.2156
Teva-Candesartan/HCTZ · DIN 02395541 · $0.2156
Shortage status: avoided shortage; reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02394812
Shortage record checked October 6, 2026
Candesartan/HCTZ · DIN 02394804 · 16 mg & 12.5 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Candesartan/HCTZ · DIN 02394804
Manufacturer: Sanis Health Inc.; listing date 2020-08-28
Health Canada: Marketed since 2024-02-21 · brand CANDESARTAN/HCTZ · ATC C09DA06 CANDERSARTAN AND DIURETICS, C09DA06 CANDERSARTAN AND DIURETICS · form Tablet · route Oral · ingredients CANDESARTAN CILEXETIL 16 MG, HYDROCHLOROTHIAZIDE 12.5 MG · company Sanis health inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordCandesartan/HCTZ: Formulary list price $0.22 per unit (the source does not state the unit; exact figure $0.2156). What the ministry pays, not the patient.
Ministry pays: $0.2156 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02394804)
Source record
DIN 02394804: Candesartan/HCTZ
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800248; group id 315; item number 0696; lccId None; manufacturer id SAI
Source form: Tab; strength: 16mg & 12.5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2156; ministry $0.2156
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02394804
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87995
Interchangeable products
Atacand Plus · DIN 02244021 · $0.2156
Auro-Candesartan HCT · DIN 02421038 · $0.2156
Candesartan HCT · DIN 02394812 · $0.2156
Jamp Candesartan-HCT · DIN 02473240 · $0.2156
NRA-Candesartan HCTZ · DIN 02531240 · $0.2156
PMS-Candesartan-HCTZ · DIN 02391295 · $0.2156
Sandoz Candesartan Plus · DIN 02327902 · $0.2156
Teva-Candesartan/HCTZ · DIN 02395541 · $0.2156
Shortage status: resolved shortage (ended April 1, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02394804
Shortage record checked October 6, 2026
Jamp Candesartan-HCT · DIN 02473240 · 16 mg & 12.5 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Jamp Candesartan-HCT · DIN 02473240
Manufacturer: Jamp Pharma Corporation; listing date 2019-07-31
Health Canada: Marketed since 2020-03-23 · brand JAMP CANDESARTAN-HCT · ATC C09DA06 CANDERSARTAN AND DIURETICS, C09DA06 CANDERSARTAN AND DIURETICS · form Tablet · route Oral · ingredients CANDESARTAN CILEXETIL 16 MG, HYDROCHLOROTHIAZIDE 12.5 MG · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordJamp Candesartan-HCT: Formulary list price $0.22 per unit (the source does not state the unit; exact figure $0.2156). What the ministry pays, not the patient.
Ministry pays: $0.2156 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02473240)
Source record
DIN 02473240: Jamp Candesartan-HCT
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800248; group id 315; item number 0696; lccId None; manufacturer id JPC
Source form: Tab; strength: 16mg & 12.5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2156; ministry $0.2156
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02473240
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96264
Interchangeable products
Atacand Plus · DIN 02244021 · $0.2156
Auro-Candesartan HCT · DIN 02421038 · $0.2156
Candesartan HCT · DIN 02394812 · $0.2156
Candesartan/HCTZ · DIN 02394804 · $0.2156
NRA-Candesartan HCTZ · DIN 02531240 · $0.2156
PMS-Candesartan-HCTZ · DIN 02391295 · $0.2156
Sandoz Candesartan Plus · DIN 02327902 · $0.2156
Teva-Candesartan/HCTZ · DIN 02395541 · $0.2156
Shortage status: resolved shortage (ended May 24, 2024); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02473240
Shortage record checked October 6, 2026
NRA-Candesartan HCTZ · DIN 02531240 · 16 mg & 12.5 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
NRA-Candesartan HCTZ · DIN 02531240
Manufacturer: Nora Pharma; listing date 2023-12-29
Health Canada: Marketed since 2023-07-20 · brand NRA-CANDESARTAN HCTZ · ATC C09DA06 CANDERSARTAN AND DIURETICS, C09DA06 CANDERSARTAN AND DIURETICS · form Tablet · route Oral · ingredients CANDESARTAN CILEXETIL 16 MG, HYDROCHLOROTHIAZIDE 12.5 MG · company Nora pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordNRA-Candesartan HCTZ: Formulary list price $0.22 per unit (the source does not state the unit; exact figure $0.2156). What the ministry pays, not the patient.
Ministry pays: $0.2156 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02531240)
Source record
DIN 02531240: NRA-Candesartan HCTZ
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800248; group id 315; item number 0696; lccId None; manufacturer id NRA
Source form: Tab; strength: 16mg & 12.5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2156; ministry $0.2156
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02531240
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102039
Interchangeable products
Atacand Plus · DIN 02244021 · $0.2156
Auro-Candesartan HCT · DIN 02421038 · $0.2156
Candesartan HCT · DIN 02394812 · $0.2156
Candesartan/HCTZ · DIN 02394804 · $0.2156
Jamp Candesartan-HCT · DIN 02473240 · $0.2156
PMS-Candesartan-HCTZ · DIN 02391295 · $0.2156
Sandoz Candesartan Plus · DIN 02327902 · $0.2156
Teva-Candesartan/HCTZ · DIN 02395541 · $0.2156
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02531240
Shortage record checked October 6, 2026
PMS-Candesartan-HCTZ · DIN 02391295 · 16 mg & 12.5 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
PMS-Candesartan-HCTZ · DIN 02391295
Manufacturer: Pharmascience Inc.; listing date 2012-11-27
Health Canada: Marketed since 2012-09-24 · brand PMS-CANDESARTAN-HCTZ · ATC C09DA06 CANDERSARTAN AND DIURETICS, C09DA06 CANDERSARTAN AND DIURETICS · form Tablet · route Oral · ingredients HYDROCHLOROTHIAZIDE 12.5 MG, CANDESARTAN CILEXETIL 16.0 MG · company Pharmascience inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordPMS-Candesartan-HCTZ: Formulary list price $0.22 per unit (the source does not state the unit; exact figure $0.2156). What the ministry pays, not the patient.
Ministry pays: $0.2156 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02391295)
Source record
DIN 02391295: PMS-Candesartan-HCTZ
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800248; group id 315; item number 0696; lccId None; manufacturer id PMS
Source form: Tab; strength: 16mg & 12.5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2156; ministry $0.2156
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02391295
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87664
Interchangeable products
Atacand Plus · DIN 02244021 · $0.2156
Auro-Candesartan HCT · DIN 02421038 · $0.2156
Candesartan HCT · DIN 02394812 · $0.2156
Candesartan/HCTZ · DIN 02394804 · $0.2156
Jamp Candesartan-HCT · DIN 02473240 · $0.2156
NRA-Candesartan HCTZ · DIN 02531240 · $0.2156
Sandoz Candesartan Plus · DIN 02327902 · $0.2156
Teva-Candesartan/HCTZ · DIN 02395541 · $0.2156
Shortage status: resolved shortage (ended February 25, 2019); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02391295
Shortage record checked October 6, 2026
Sandoz Candesartan Plus · DIN 02327902 · 16 mg & 12.5 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Sandoz Candesartan Plus · DIN 02327902
Manufacturer: Sandoz Canada Inc.; listing date 2012-11-27
Health Canada: Marketed since 2012-09-24 · brand SANDOZ CANDESARTAN PLUS · ATC C09DA06 CANDERSARTAN AND DIURETICS, C09DA06 CANDERSARTAN AND DIURETICS · form Tablet · route Oral · ingredients HYDROCHLOROTHIAZIDE 12.5 MG, CANDESARTAN CILEXETIL 16 MG · company Sandoz canada incorporated · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordSandoz Candesartan Plus: Formulary list price $0.22 per unit (the source does not state the unit; exact figure $0.2156). What the ministry pays, not the patient.
Ministry pays: $0.2156 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02327902)
Source record
DIN 02327902: Sandoz Candesartan Plus
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800248; group id 315; item number 0696; lccId None; manufacturer id SDZ
Source form: Tab; strength: 16mg & 12.5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2156; ministry $0.2156
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02327902
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81340
Interchangeable products
Atacand Plus · DIN 02244021 · $0.2156
Auro-Candesartan HCT · DIN 02421038 · $0.2156
Candesartan HCT · DIN 02394812 · $0.2156
Candesartan/HCTZ · DIN 02394804 · $0.2156
Jamp Candesartan-HCT · DIN 02473240 · $0.2156
NRA-Candesartan HCTZ · DIN 02531240 · $0.2156
PMS-Candesartan-HCTZ · DIN 02391295 · $0.2156
Teva-Candesartan/HCTZ · DIN 02395541 · $0.2156
Shortage status: resolved shortage (ended September 14, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02327902
Shortage record checked October 6, 2026
Teva-Candesartan/HCTZ · DIN 02395541 · 16 mg & 12.5 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Teva-Candesartan/HCTZ · DIN 02395541
Manufacturer: Teva Canada Limited; listing date 2012-12-21
Health Canada: Marketed since 2013-09-23 · brand TEVA-CANDESARTAN/HCTZ · ATC C09DA06 CANDERSARTAN AND DIURETICS, C09DA06 CANDERSARTAN AND DIURETICS · form Tablet · route Oral · ingredients HYDROCHLOROTHIAZIDE 12.5 MG, CANDESARTAN CILEXETIL 16 MG · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordTeva-Candesartan/HCTZ: Formulary list price $0.22 per unit (the source does not state the unit; exact figure $0.2156). What the ministry pays, not the patient.
Ministry pays: $0.2156 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02395541)
Source record
DIN 02395541: Teva-Candesartan/HCTZ
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800248; group id 315; item number 0696; lccId None; manufacturer id TEV
Source form: Tab; strength: 16mg & 12.5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2156; ministry $0.2156
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02395541
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88063
Interchangeable products
Atacand Plus · DIN 02244021 · $0.2156
Auro-Candesartan HCT · DIN 02421038 · $0.2156
Candesartan HCT · DIN 02394812 · $0.2156
Candesartan/HCTZ · DIN 02394804 · $0.2156
Jamp Candesartan-HCT · DIN 02473240 · $0.2156
NRA-Candesartan HCTZ · DIN 02531240 · $0.2156
PMS-Candesartan-HCTZ · DIN 02391295 · $0.2156
Sandoz Candesartan Plus · DIN 02327902 · $0.2156
Shortage status: shortage reported ended May 5, 2026 (report last updated May 5, 2026); confirm supply with the pharmacy; reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02395541
Shortage record checked October 6, 2026
Atacand Plus · DIN 02332922 · 32 mg & 12.5 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
1 brand, same coverage
Atacand Plus · DIN 02332922
Manufacturer: Cheplapharm Arzneimittel GmbH; listing date 2010-07-20
Health Canada: Marketed since 2025-06-19 · brand ATACAND PLUS · ATC C09DA06 CANDERSARTAN AND DIURETICS, C09DA06 CANDERSARTAN AND DIURETICS · form Tablet · route Oral · ingredients HYDROCHLOROTHIAZIDE 12.5 MG, CANDESARTAN CILEXETIL 32 MG · company Cheplapharm arzneimittel gmbh · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordMinistry pays: $0.2156 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02332922)
Source record
DIN 02332922: Atacand Plus
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800291; group id 315; item number 0697; lccId None; manufacturer id CHE
Source form: Tab; strength: 32mg & 12.5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $1.6162; ministry $0.2156
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02332922
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81858
Interchangeable products
Auro-Candesartan HCT · DIN 02421046 · $0.2156
Candesartan/HCTZ · DIN 02536064 · $0.2156
Jamp Candesartan-HCT · DIN 02473259 · $0.2156
NRA-Candesartan HCTZ · DIN 02531259 · $0.2156
Sandoz Candesartan Plus · DIN 02420732 · $0.2156
Teva-Candesartan/HCTZ · DIN 02395568 · $0.2156
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02332922
Shortage record checked October 6, 2026
Atacand Plus · DIN 02332957 · 32 mg & 25 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
1 brand, same coverage
Atacand Plus · DIN 02332957
Manufacturer: Cheplapharm Arzneimittel GmbH; listing date 2010-07-20
Health Canada: Marketed since 2025-06-25 · brand ATACAND PLUS · ATC C09DA06 CANDERSARTAN AND DIURETICS, C09DA06 CANDERSARTAN AND DIURETICS · form Tablet · route Oral · ingredients CANDESARTAN CILEXETIL 32 MG, HYDROCHLOROTHIAZIDE 25 MG · company Cheplapharm arzneimittel gmbh · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordMinistry pays: $0.3008 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02332957)
Source record
DIN 02332957: Atacand Plus
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800292; group id 315; item number 0698; lccId None; manufacturer id CHE
Source form: Tab; strength: 32mg & 25mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $1.6162; ministry $0.3008
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02332957
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81859
Interchangeable products
Auro-Candesartan HCT · DIN 02421054 · $0.3008
Jamp Candesartan-HCT · DIN 02473267 · $0.3008
NRA-Candesartan HCTZ · DIN 02531267 · $0.3008
Sandoz Candesartan Plus · DIN 02420740 · $0.3008
Shortage status: resolved shortage (ended April 1, 2020); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02332957
Shortage record checked October 6, 2026
Auro-Candesartan HCT · DIN 02421046 · 32 mg & 12.5 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Auro-Candesartan HCT · DIN 02421046
Manufacturer: Auro Pharma Inc.; listing date 2015-05-28
Health Canada: Marketed since 2015-03-17 · brand AURO-CANDESARTAN HCT · ATC C09DA06 CANDERSARTAN AND DIURETICS, C09DA06 CANDERSARTAN AND DIURETICS · form Tablet · route Oral · ingredients HYDROCHLOROTHIAZIDE 12.5 MG, CANDESARTAN CILEXETIL 32 MG · company Auro pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordAuro-Candesartan HCT: Formulary list price $0.22 per unit (the source does not state the unit; exact figure $0.2156). What the ministry pays, not the patient.
Ministry pays: $0.2156 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02421046)
Source record
DIN 02421046: Auro-Candesartan HCT
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800291; group id 315; item number 0697; lccId None; manufacturer id AUR
Source form: Tab; strength: 32mg & 12.5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2156; ministry $0.2156
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02421046
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90563
Interchangeable products
Atacand Plus · DIN 02332922 · $0.2156
Candesartan/HCTZ · DIN 02536064 · $0.2156
Jamp Candesartan-HCT · DIN 02473259 · $0.2156
NRA-Candesartan HCTZ · DIN 02531259 · $0.2156
Sandoz Candesartan Plus · DIN 02420732 · $0.2156
Teva-Candesartan/HCTZ · DIN 02395568 · $0.2156
Shortage status: resolved shortage (ended February 18, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02421046
Shortage record checked October 6, 2026
Auro-Candesartan HCT · DIN 02421054 · 32 mg & 25 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Auro-Candesartan HCT · DIN 02421054
Manufacturer: Auro Pharma Inc.; listing date 2015-05-28
Health Canada: Marketed since 2015-03-17 · brand AURO-CANDESARTAN HCT · ATC C09DA06 CANDERSARTAN AND DIURETICS, C09DA06 CANDERSARTAN AND DIURETICS · form Tablet · route Oral · ingredients HYDROCHLOROTHIAZIDE 25 MG, CANDESARTAN CILEXETIL 32 MG · company Auro pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordAuro-Candesartan HCT: Formulary list price $0.30 per unit (the source does not state the unit; exact figure $0.3008). What the ministry pays, not the patient.
Ministry pays: $0.3008 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02421054)
Source record
DIN 02421054: Auro-Candesartan HCT
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800292; group id 315; item number 0698; lccId None; manufacturer id AUR
Source form: Tab; strength: 32mg & 25mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.3008; ministry $0.3008
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02421054
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90564
Interchangeable products
Atacand Plus · DIN 02332957 · $0.3008
Jamp Candesartan-HCT · DIN 02473267 · $0.3008
NRA-Candesartan HCTZ · DIN 02531267 · $0.3008
Sandoz Candesartan Plus · DIN 02420740 · $0.3008
Shortage status: active shortage (reported June 18, 2026, estimated to end September 30, 2026, last updated August 31, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02421054
Shortage record checked October 6, 2026
Candesartan/HCTZ · DIN 02536064 · 32 mg & 12.5 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Candesartan/HCTZ · DIN 02536064
Manufacturer: Sanis Health Inc.; listing date 2024-04-30
Health Canada: Marketed since 2024-02-21 · brand CANDESARTAN/HCTZ · ATC C09DA06 CANDERSARTAN AND DIURETICS, C09DA06 CANDERSARTAN AND DIURETICS · form Tablet · route Oral · ingredients CANDESARTAN CILEXETIL 32 MG, HYDROCHLOROTHIAZIDE 12.5 MG · company Sanis health inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordCandesartan/HCTZ: Formulary list price $0.22 per unit (the source does not state the unit; exact figure $0.2156). What the ministry pays, not the patient.
Ministry pays: $0.2156 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02536064)
Source record
DIN 02536064: Candesartan/HCTZ
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800291; group id 315; item number 0697; lccId None; manufacturer id SAI
Source form: Tab; strength: 32mg & 12.5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2156; ministry $0.2156
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02536064
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102488
Interchangeable products
Atacand Plus · DIN 02332922 · $0.2156
Auro-Candesartan HCT · DIN 02421046 · $0.2156
Jamp Candesartan-HCT · DIN 02473259 · $0.2156
NRA-Candesartan HCTZ · DIN 02531259 · $0.2156
Sandoz Candesartan Plus · DIN 02420732 · $0.2156
Teva-Candesartan/HCTZ · DIN 02395568 · $0.2156
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02536064
Shortage record checked October 6, 2026
Jamp Candesartan-HCT · DIN 02473259 · 32 mg & 12.5 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Jamp Candesartan-HCT · DIN 02473259
Manufacturer: Jamp Pharma Corporation; listing date 2019-07-31
Health Canada: Marketed since 2020-03-23 · brand JAMP CANDESARTAN-HCT · ATC C09DA06 CANDERSARTAN AND DIURETICS, C09DA06 CANDERSARTAN AND DIURETICS · form Tablet · route Oral · ingredients HYDROCHLOROTHIAZIDE 12.5 MG, CANDESARTAN CILEXETIL 32 MG · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordJamp Candesartan-HCT: Formulary list price $0.22 per unit (the source does not state the unit; exact figure $0.2156). What the ministry pays, not the patient.
Ministry pays: $0.2156 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02473259)
Source record
DIN 02473259: Jamp Candesartan-HCT
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800291; group id 315; item number 0697; lccId None; manufacturer id JPC
Source form: Tab; strength: 32mg & 12.5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2156; ministry $0.2156
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02473259
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96265
Interchangeable products
Atacand Plus · DIN 02332922 · $0.2156
Auro-Candesartan HCT · DIN 02421046 · $0.2156
Candesartan/HCTZ · DIN 02536064 · $0.2156
NRA-Candesartan HCTZ · DIN 02531259 · $0.2156
Sandoz Candesartan Plus · DIN 02420732 · $0.2156
Teva-Candesartan/HCTZ · DIN 02395568 · $0.2156
Shortage status: resolved shortage (ended May 24, 2024); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02473259
Shortage record checked October 6, 2026
Jamp Candesartan-HCT · DIN 02473267 · 32 mg & 25 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Jamp Candesartan-HCT · DIN 02473267
Manufacturer: Jamp Pharma Corporation; listing date 2019-07-31
Health Canada: Marketed since 2020-03-23 · brand JAMP CANDESARTAN-HCT · ATC C09DA06 CANDERSARTAN AND DIURETICS, C09DA06 CANDERSARTAN AND DIURETICS · form Tablet · route Oral · ingredients HYDROCHLOROTHIAZIDE 25 MG, CANDESARTAN CILEXETIL 32 MG · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordJamp Candesartan-HCT: Formulary list price $0.30 per unit (the source does not state the unit; exact figure $0.3008). What the ministry pays, not the patient.
Ministry pays: $0.3008 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02473267)
Source record
DIN 02473267: Jamp Candesartan-HCT
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800292; group id 315; item number 0698; lccId None; manufacturer id JPC
Source form: Tab; strength: 32mg & 25mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.3008; ministry $0.3008
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02473267
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96266
Interchangeable products
Atacand Plus · DIN 02332957 · $0.3008
Auro-Candesartan HCT · DIN 02421054 · $0.3008
NRA-Candesartan HCTZ · DIN 02531267 · $0.3008
Sandoz Candesartan Plus · DIN 02420740 · $0.3008
Shortage status: resolved shortage (ended May 31, 2024); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02473267
Shortage record checked October 6, 2026
NRA-Candesartan HCTZ · DIN 02531259 · 32 mg & 12.5 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
NRA-Candesartan HCTZ · DIN 02531259
Manufacturer: Nora Pharma; listing date 2023-12-29
Health Canada: Marketed since 2023-07-20 · brand NRA-CANDESARTAN HCTZ · ATC C09DA06 CANDERSARTAN AND DIURETICS, C09DA06 CANDERSARTAN AND DIURETICS · form Tablet · route Oral · ingredients HYDROCHLOROTHIAZIDE 12.5 MG, CANDESARTAN CILEXETIL 32 MG · company Nora pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordNRA-Candesartan HCTZ: Formulary list price $0.22 per unit (the source does not state the unit; exact figure $0.2156). What the ministry pays, not the patient.
Ministry pays: $0.2156 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02531259)
Source record
DIN 02531259: NRA-Candesartan HCTZ
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800291; group id 315; item number 0697; lccId None; manufacturer id NRA
Source form: Tab; strength: 32mg & 12.5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2156; ministry $0.2156
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02531259
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102040
Interchangeable products
Atacand Plus · DIN 02332922 · $0.2156
Auro-Candesartan HCT · DIN 02421046 · $0.2156
Candesartan/HCTZ · DIN 02536064 · $0.2156
Jamp Candesartan-HCT · DIN 02473259 · $0.2156
Sandoz Candesartan Plus · DIN 02420732 · $0.2156
Teva-Candesartan/HCTZ · DIN 02395568 · $0.2156
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02531259
Shortage record checked October 6, 2026
NRA-Candesartan HCTZ · DIN 02531267 · 32 mg & 25 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
NRA-Candesartan HCTZ · DIN 02531267
Manufacturer: Nora Pharma; listing date 2023-12-29
Health Canada: Marketed since 2023-07-20 · brand NRA-CANDESARTAN HCTZ · ATC C09DA06 CANDERSARTAN AND DIURETICS, C09DA06 CANDERSARTAN AND DIURETICS · form Tablet · route Oral · ingredients HYDROCHLOROTHIAZIDE 25 MG, CANDESARTAN CILEXETIL 32 MG · company Nora pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordNRA-Candesartan HCTZ: Formulary list price $0.30 per unit (the source does not state the unit; exact figure $0.3008). What the ministry pays, not the patient.
Ministry pays: $0.3008 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02531267)
Source record
DIN 02531267: NRA-Candesartan HCTZ
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800292; group id 315; item number 0698; lccId None; manufacturer id NRA
Source form: Tab; strength: 32mg & 25mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.3008; ministry $0.3008
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02531267
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102041
Interchangeable products
Atacand Plus · DIN 02332957 · $0.3008
Auro-Candesartan HCT · DIN 02421054 · $0.3008
Jamp Candesartan-HCT · DIN 02473267 · $0.3008
Sandoz Candesartan Plus · DIN 02420740 · $0.3008
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02531267
Shortage record checked October 6, 2026
Sandoz Candesartan Plus · DIN 02420732 · 32 mg & 12.5 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Sandoz Candesartan Plus · DIN 02420732
Manufacturer: Sandoz Canada Inc.; listing date 2014-07-30
Health Canada: Marketed since 2014-02-12 · brand SANDOZ CANDESARTAN PLUS · ATC C09DA06 CANDERSARTAN AND DIURETICS, C09DA06 CANDERSARTAN AND DIURETICS · form Tablet · route Oral · ingredients HYDROCHLOROTHIAZIDE 12.5 MG, CANDESARTAN CILEXETIL 32 MG · company Sandoz canada incorporated · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordSandoz Candesartan Plus: Formulary list price $0.22 per unit (the source does not state the unit; exact figure $0.2156). What the ministry pays, not the patient.
Ministry pays: $0.2156 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02420732)
Source record
DIN 02420732: Sandoz Candesartan Plus
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800291; group id 315; item number 0697; lccId None; manufacturer id SDZ
Source form: Tab; strength: 32mg & 12.5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2156; ministry $0.2156
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02420732
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90530
Interchangeable products
Atacand Plus · DIN 02332922 · $0.2156
Auro-Candesartan HCT · DIN 02421046 · $0.2156
Candesartan/HCTZ · DIN 02536064 · $0.2156
Jamp Candesartan-HCT · DIN 02473259 · $0.2156
NRA-Candesartan HCTZ · DIN 02531259 · $0.2156
Teva-Candesartan/HCTZ · DIN 02395568 · $0.2156
Shortage status: resolved shortage (ended August 24, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02420732
Shortage record checked October 6, 2026
Sandoz Candesartan Plus · DIN 02420740 · 32 mg & 25 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Sandoz Candesartan Plus · DIN 02420740
Manufacturer: Sandoz Canada Inc.; listing date 2014-07-30
Health Canada: Marketed since 2014-02-12 · brand SANDOZ CANDESARTAN PLUS · ATC C09DA06 CANDERSARTAN AND DIURETICS, C09DA06 CANDERSARTAN AND DIURETICS · form Tablet · route Oral · ingredients HYDROCHLOROTHIAZIDE 25 MG, CANDESARTAN CILEXETIL 32 MG · company Sandoz canada incorporated · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordSandoz Candesartan Plus: Formulary list price $0.30 per unit (the source does not state the unit; exact figure $0.3008). What the ministry pays, not the patient.
Ministry pays: $0.3008 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02420740)
Source record
DIN 02420740: Sandoz Candesartan Plus
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800292; group id 315; item number 0698; lccId None; manufacturer id SDZ
Source form: Tab; strength: 32mg & 25mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.3008; ministry $0.3008
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02420740
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90531
Interchangeable products
Atacand Plus · DIN 02332957 · $0.3008
Auro-Candesartan HCT · DIN 02421054 · $0.3008
Jamp Candesartan-HCT · DIN 02473267 · $0.3008
NRA-Candesartan HCTZ · DIN 02531267 · $0.3008
Shortage status: resolved shortage (ended June 8, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02420740
Shortage record checked October 6, 2026
Teva-Candesartan/HCTZ · DIN 02395568 · 32 mg & 12.5 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Teva-Candesartan/HCTZ · DIN 02395568
Manufacturer: Teva Canada Limited; listing date 2013-06-27
Health Canada: Marketed since 2013-06-19 · brand TEVA-CANDESARTAN/HCTZ · ATC C09DA06 CANDERSARTAN AND DIURETICS, C09DA06 CANDERSARTAN AND DIURETICS · form Tablet · route Oral · ingredients HYDROCHLOROTHIAZIDE 12.5 MG, CANDESARTAN CILEXETIL 32 MG · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordTeva-Candesartan/HCTZ: Formulary list price $0.22 per unit (the source does not state the unit; exact figure $0.2156). What the ministry pays, not the patient.
Ministry pays: $0.2156 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02395568)
Source record
DIN 02395568: Teva-Candesartan/HCTZ
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800291; group id 315; item number 0697; lccId None; manufacturer id TEV
Source form: Tab; strength: 32mg & 12.5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2156; ministry $0.2156
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02395568
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88064
Interchangeable products
Atacand Plus · DIN 02332922 · $0.2156
Auro-Candesartan HCT · DIN 02421046 · $0.2156
Candesartan/HCTZ · DIN 02536064 · $0.2156
Jamp Candesartan-HCT · DIN 02473259 · $0.2156
NRA-Candesartan HCTZ · DIN 02531259 · $0.2156
Sandoz Candesartan Plus · DIN 02420732 · $0.2156
Shortage status: shortage reported ended May 5, 2026 (report last updated May 5, 2026); confirm supply with the pharmacy; reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02395568
Shortage record checked October 6, 2026
Other products in the same Health Canada class (C09DA): coverage varies; not interchangeable
- Hydrochlorothiazide + irbesartan (Avalide): general benefit, not a benefit
- Hydrochlorothiazide + losartan (Hyzaar): general benefit
- Hydrochlorothiazide + olmesartan medoxomil (Olmetec Plus): general benefit
- Hydrochlorothiazide + telmisartan (Micardis Plus): general benefit
- Hydrochlorothiazide + valsartan (Diovan-HCT): general benefit
- Eprosartan + hydrochlorothiazide (Teveten Plus): general benefit
1 more in the class list below
Other drugs in the same formulary class (24:08 Hypotensive Drugs (For Diuretics See 40:28)) and how they are covered
Matched class: 24:08 Hypotensive Drugs (For Diuretics See 40:28)
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Covered without a code on the Ontario formulary: CANDESARTAN CILEXETIL, CILAZAPRIL & HYDROCHLOROTHIAZIDE, LABETALOL HCL, LOSARTAN POTASSIUM, LOSARTAN POTASSIUM & HYDROCHLOROTHIAZIDE, MINOXIDIL, OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL & HYDROCHLOROTHIAZIDE, PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE & INDAPAMIDE, PINDOLOL & HYDROCHLOROTHIAZIDE, TELMISARTAN, TELMISARTAN & AMLODIPINE BESYLATE, TELMISARTAN & HYDROCHLOROTHIAZIDE, VALSARTAN & HYDROCHLOROTHIAZIDE
Some products covered without a code (check the product listing): ATENOLOL & CHLORTHALIDONE, BENAZEPRIL, CAPTOPRIL, CILAZAPRIL, CLONIDINE HCL, DOXAZOSIN MESYLATE, ENALAPRIL MALEATE, FELODIPINE, FOSINOPRIL SODIUM, HYDRALAZINE HCL, IRBESARTAN, IRBESARTAN & HYDROCHLOROTHIAZIDE, LISINOPRIL, LISINOPRIL & HYDROCHLOROTHIAZIDE, METHYLDOPA, NIFEDIPINE, PINDOLOL, PRAZOSIN HCL, QUINAPRIL, QUINAPRIL & HYDROCHLOROTHIAZIDE, RAMIPRIL, RAMIPRIL & HYDROCHLOROTHIAZIDE, TERAZOSIN HCL, TRANDOLAPRIL, VALSARTAN, VERAPAMIL HCL
24:08 Hypotensive Drugs (For Diuretics See 40:28)
· 36 products · General benefit (35), Listed, not a benefit (1) · strengths: 150mg & 12.5mg, 300mg & 12.5mg, 300mg & 25mg · Tab
· 34 products · General benefit · strengths: 100mg & 12.5mg, 50mg & 12.5mg, 100mg & 25mg · Tab
· 27 products · General benefit · strengths: 20mg & 12.5mg, 40mg & 12.5mg, 40mg & 25mg · Tab
· 22 products · General benefit · strengths: 80mg & 12.5mg, 80mg & 25mg · Tab
· 34 products · General benefit · strengths: 80mg & 12.5mg, 160mg & 12.5mg, 160mg & 25mg, 320mg & 12.5mg, 320mg & 25mg · Tab
· 1 products · General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada · strengths: 600mg & 12.5mg · Tab
· 8 products · General benefit · strengths: 40mg & 10mg, 40mg & 5mg, 80mg & 10mg, 80mg & 5mg · Tab
· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 50 & 25mg, 100 & 25mg · Tab
· 6 products · Listed, not a benefit (3), General benefit (3) · strengths: 5mg, 10mg, 20mg · Tab
· 59 products · General benefit · strengths: 4mg, 8mg, 16mg, 32mg · Tab
· 14 products ·
Limited Use, codes 707, 723 (2), Listed, not a benefit (4), General benefit (8) · strengths: 5mg/5mL, 25mg/5mL, 12.5mg, 25mg, 50mg, 100mg · Oral Sol, Tab
· 8 products · Listed, not a benefit (2), General benefit (6) · strengths: 1mg, 2.5mg, 5mg · Tab
Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 24:08
and 35 more
Full class listing
Related classes: 24:04 Cardiac Drugs, 24:06 Antilipemic Drugs, 24:12 Vasodilating Drugs, 24:32 Renin-Angiotensin Aldosterone Inhibitors
Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: hypertension
From Health Canada product monographs; label wording only, not a treatment recommendation.
Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ.
Covered without a code on the Ontario formulary: CANDESARTAN CILEXETIL, CILAZAPRIL & HYDROCHLOROTHIAZIDE
ACEBUTOLOL HCL · Listed, not a benefit (3), General benefit (6)
INDICATIONS AND CLINICAL USE
APO-ACEBUTOLOL is indicated for the following:
Treatment of mild to moderate hypertension.
Long-term management of patients with angina pectoris due to ischemic heart disease.
PM: https://pdf.hres.ca/dpd_pm/00047998.PDF; date October 24, 2018; DIN 02147602; fetched 2026-09-10
Product monograph
AMLODIPINE · Limited Use, codes 645, 706 (1), Off-Formulary Interchangeable, not an ODB benefit (12), General benefit (46)
1 INDICATIONS
NORVASC (amlodipine besylate tablets) is indicated for:
• Hypertension
NORVASC is indicated in the treatment of mild to moderate essential hypertension.
PM: https://pdf.hres.ca/dpd_pm/00071908.PDF; date AUG 02, 2023; DIN 00878928; fetched 2026-09-10
Product monograph
AZILSARTAN MEDOXOMIL · Off-Formulary Interchangeable, not an ODB benefit
1 Part 1: Healthcare Professional Information Indications
• EDARBI (azilsartan medoxomil) is an angiotensin II receptor blocker (ARB) indicated for the
treatment of mild to moderate essential hypertension.
PM: https://pdf.hres.ca/dpd_pm/00082489.PDF; date 2025-10-24; DIN 02381389; fetched 2026-09-10
Product monograph
BENAZEPRIL · Listed, not a benefit (3), General benefit (3)
Indications
BENAZEPRIL (benazepril hydrochloride tablets) is indicated for:
Treatment of mild to moderate essential hypertension.
PM: https://pdf.hres.ca/dpd_pm/00080887.PDF; date 2025-06-24; DIN 02273918; fetched 2026-09-10
Product monograph
CANDESARTAN CILEXETIL · General benefit
• Heart Failure
o The treatment of NYHA Class II and III heart failure with ejection fraction ≤ 40% in
addition to standard therapy, with or without an ACE inhibitor.
1.1 Pediatrics
Pediatrics (6 to 17 years of age):
• Hypertension
ATACAND is indicated for the treatment of essential hypertension in children and
adolescents 6 to 17 years of age (see 7.1.3 Pediatrics, 14 CLINICAL TRIALS).
PM: https://pdf.hres.ca/dpd_pm/00085412.PDF; date JUL 17, 2026; DIN 02239090; fetched 2026-09-10
Product monograph
• Hypertension
PM: https://pdf.hres.ca/dpd_pm/00085412.PDF; date JUL 17, 2026; DIN 02239090; fetched 2026-09-10
Product monograph
CHLORTHALIDONE · Listed, not a benefit (1), General benefit (2)
1 INDICATIONS
APO-CHLORTHALIDONE (chlorthalidone) is indicated for:
• Treatment of hypertension.
PM: https://pdf.hres.ca/dpd_pm/00069909.PDF; date MAR 14, 2023; DIN 00360279; fetched 2026-09-10
Product monograph
CILAZAPRIL & HYDROCHLOROTHIAZIDE · General benefit
1 INDICATIONS
INHIBACE PLUS (cilazapril and hydrochlorothiazide) is indicated for:
treatment of mild to moderate essential hypertension in patients for whom combination therapy
with both cilazapril and hydrochlorothiazide is appropriate.
PM: https://pdf.hres.ca/dpd_pm/00066994.PDF; date September 07, 1995; DIN 02181479; fetched 2026-09-10
Product monograph
CLONIDINE HCL · Off-Formulary Interchangeable, not an ODB benefit (7), Listed, not a benefit (2), General benefit (8)
INDICATIONS AND CLINICAL USE
TEVA-CLONIDINE (clonidine hydrochloride) is indicated for the treatment of hypertension.
PM: https://pdf.hres.ca/dpd_pm/00024986.PDF; date April 25, 2014; DIN 02046121; fetched 2026-09-10
Product monograph
ENALAPRIL MALEATE & HYDROCHLOROTHIAZIDE · Off-Formulary Interchangeable, not an ODB benefit
1 INDICATIONS
VASERETIC® (enalapril and hydrochlorothiazide) is indicated for:
Treatment of essential hypertension in patients for whom this combination therapy with
enalapril and hydrochlorothiazide is appropriate.
PM: https://pdf.hres.ca/dpd_pm/00068096.PDF; date November 4, 2022; DIN 00657298; fetched 2026-09-10
Product monograph
FELODIPINE · General benefit (10), Listed, not a benefit (2)
1 INDICATIONS
PLENDIL (felodipine) is indicated for:
• the treatment of mild to moderate essential hypertension.
PM: https://pdf.hres.ca/dpd_pm/00082730.PDF; date 2025-12-09; DIN 00851779; fetched 2026-09-10
Product monograph
and 20 more
Coverage source: ON formulary extract 2026-09-22